Literature DB >> 1792977

Gamma knife surgery for cerebral metastasis.

L Kihlström1, B Karlsson, C Lindquist, G Norén, T Rähn.   

Abstract

Twenty-six cerebral metastatic tumours treated with the Gamma knife employing a large single dose were followed by repeated clinical and CT examinations. In most cases Gamma knife surgery was the only treatment. The follow up time has been longer than 6 months with a median follow up of 9 months. In all but one of the cases a remarkable progressive shrinkage of the tumour started 2-4 months after the therapy. The therapeutic results indicate that radiosurgery used even as the only form of treatment is the best treatment alternative for cerebral metastasis presently available.

Entities:  

Mesh:

Year:  1991        PMID: 1792977     DOI: 10.1007/978-3-7091-9160-6_25

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  5 in total

1.  Role of stereotactic biopsy in multifocal brain lesions: considerations on 100 consecutive cases.

Authors:  A Franzini; F Leocata; C Giorgi; A Allegranza; D Servello; G Broggi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

2.  Stereotactic radiosurgery for brain metastases: comparison of lung carcinoma vs. non-lung tumors.

Authors:  J Williams; C Enger; M Wharam; D Tsai; H Brem
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

3.  Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer.

Authors:  In-Young Kim; Douglas Kondziolka; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

4.  The role of adjuvant radiation and multiple resection within the surgical management of brain metastases.

Authors:  F Weber; A Riedel; W Köning; J Menzel
Journal:  Neurosurg Rev       Date:  1996       Impact factor: 3.042

5.  A retrospective study of SBRT of metastases in patients with primary sarcoma.

Authors:  Christina Linder Stragliotto; Kristin Karlsson; Ingmar Lax; Eva Rutkowska; Jonas Bergh; Hans Strander; Henric Blomgren; Signe Friesland
Journal:  Med Oncol       Date:  2012-07-20       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.